A

Asan Medical Center | Clinical Trial Center

Research site
(Unclaimed)
Location
88 Olympic-ro 43 gil, Songpa-gu, Seoul, Seoul, South Korea

Site insights

Top conditions

Top treatments

Atezolizumab
Paclitaxel
Pembrolizumab
Bevacizumab
Carboplatin
Cisplatin
Trastuzumab
Gemcitabine
Capecitabine
Docetaxel

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

540 of 1906 total trials

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monot...

Active, not recruiting
Brain Metastases
Neoplasms by Site
Drug: Carboplatin
Drug: Pemetrexed

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll...

Enrolling
Metastatic Cancer
Advanced Gastrointestinal Stromal Tumors
Drug: CGT9486
Drug: Sunitinib

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (I...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV Trial to evaluate the efficacy and safety of Choline Alfoscerate compa...

Not yet enrolling
Vascular Cognitive Impairment
Drug: Choline Alfoscerate 400mg
Drug: Placebo of Choline Alfoscerate 400mg

This is a randomized, double-blind, multi-center, therapeutic confirmatory, phase 3 trial to evaluate the efficacy and safety of CKD-391 and CKD-331...

Enrolling
Primary Hypercholesterolemia
Drug: Placebo (for CKD-331)
Drug: CKD-331

The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary pressure wire-based index for assessing the ischemic potent...

Active, not recruiting
Coronary Disease
Coronary Stenosis
Procedure: FFR guided PCI
Device: Resolute Integrity Stent

This randomized controlled confirmatory study will be evaluating an mobile application, MORA Cure (ETH-01K), owned by EverEx, Inc., to examine safety...

Not yet enrolling
Patellofemoral Pain Syndrome
Other: Treatment as Usual
Device: MORA Cure

This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent lomvastomig (RO7121661), an anti PD-1...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Metastatic Melanoma
Drug: Lomvastomig

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment...

Active, not recruiting
T-cell Lymphoma
Drug: CPI-818

This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage...

Active, not recruiting
HER2-expressing Cancers
Drug: ZW49

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...

Enrolling
Waldenström Macroglobulinemia
Marginal Zone Lymphoma
Drug: BGB-16673

Researchers are looking for a better way to treat people who have advanced solid tumors including a specific kind of lung cancer (non-small cell lung...

Enrolling
Advanced Solid Tumors
Non-small Cell Lung Cancer
Drug: BAY2862789

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

Active, not recruiting
HER2-positive Endometrial Cancer
HER2-positive Colorectal Cancer
Drug: BDC-1001
Drug: Nivolumab

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling
Crohn's Disease
Drug: Mirikizumab

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical resp...

Active, not recruiting
Ulcerative Colitis
Drug: Placebo SC
Drug: Mirikizumab SC

This study aims to assess objective response rate of modified FOLFIRINOX in advanced urachaus cancer.Patients with locally advanced, recurrent, or me...

Enrolling
Urachal Cancer
Drug: FOLFIRINOX

To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free sur...

Enrolling
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Drug: Fuzuloparib Placebo, Abiraterone acetate and Prednisone
Drug: Fuzuloparib , Abiraterone acetate and Prednisone

This study aims to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles following multiple subcutaneous injectio...

Enrolling
Adult Subjects With Mild Allergic Diseases
Atopic Healthy Subjects
Drug: YH35324
Drug: Omalizumab

Trial sponsors

A
Roche logo
S
Pfizer logo
J
AbbVie logo
Boehringer Ingelheim logo
Amgen logo
Lilly logo
Gilead Sciences logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems